Trial Information

Basal Cell Carcinoma Recurrence

Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer in the United States,
affecting nearly one million of all Americans. While BCC is rarely mortal, it has
significant associated physical, psychological, and monetary costs to patients such as
disfigurement and sensory loss. Individuals who have been diagnosed with at least one BCC
lesion are likely to be diagnosed with more in the future. Treatment of these lesions and
recurrent physician appointments can be a great inconvenience to patients, resulting in
expenses to patients and loss of work and family time.

The Mohs surgery technique is associated with a low recurrence rate for BCC and is preferred
for higher risk tumors and for tumors in cosmetically sensitive sites on the head and neck.
While recurrence rates of BCC post Mohs are 1-2% for primary basal cells, recent data is not
available to validate this historical assessment. Currently, comprehensive rates of
recurrence are not available because a national registry of recurrence rates for BCC and
squamous cell carcinoma (SCC) does not exist.

The purpose of this study is to both historically and prospectively assess current basal
cell carcinoma recurrence rates in patients undergoing Mohs micrographic surgery.